Endogenous basic fibroblast growth factor displaced by heparin from the lumenal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall

Circulation

Volumn 95, Issue 7, 1997, Pages 1853-1862

  Medalion, Benjamin ^a   Merin, Gideon ^a   Aingorn, Helena ^a   Miao, Hua Quan ^a   Nagler, Arnon ^a   Elami, Amir ^a   Ishai Michaeli, Rivka ^a   Vlodavsky, Israel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

cells, smooth muscle; growth inhibitory substances; heparin; veins

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; HEPARIN; IODINE 125; PHENOXYACETIC ACID DERIVATIVE; POLYMER; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RG 13577; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DNA SYNTHESIS; HEPARINIZATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OPEN HEART SURGERY; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; SAPHENOUS VEIN; SMOOTH MUSCLE FIBER; TISSUE PERFUSION; VEIN INJURY;

EID: 0030942264     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1853     Document Type: Article

References (53)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
3. Grondin CM. Late results of coronary artery grafting: is there a flag on the field? J Thorac Cardiovasc Surg. 1984;87:161-166.
4. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82: 2190-2200.
5. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1992;86:723-729.
6. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors: implications for the pathogenesis of atherosclerosis. Arteriosclerosis. 1989;9:269-278.
7. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575-606.
8. Vlodavsky I, Greenburg G, Johnson LK, Gospodarowicz D. Vascular endothelial cells maintained in the absence of fibroblast growth factor undergo structural and functional alterations that are incompatible with their in vivo differentiated properties. J Cell Biol. 1979;83:468-486.
9. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
10. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739-3743.
11. Casscells W, Lappi DA, Olwin BB, Wai C, Siegman M, Speir EH, Sasse J, Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992;89:7159-7163.
12. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol. 1988;130:393-400.
13. Vlodavsky I, Bar-Shavit R, Korner G, Fuks Z. Extracellular matrix-bound growth factors, enzymes and plasma proteins. In: Timpl R, Rohrbach DH, eds. Basement Membranes: Cellular and Molecular Aspects. Orlando, Fla: Academic Press, Inc; 1993: 327-343.
14. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell. 1991;64:867-869.
15. Cardon-Cardo C, Vlodavsky I, Haimovitz-Friedman A, Hicklin D, Fuks Z. Expression of basic fibroblast growth factor in normal human tissues. Lab Invest. 1990;63:832-840.
16. Bashkin P, Neufeld G, Gitay GH, Vlodavsky I. Release of cell surface-associated basic fibroblast growth factor by glycosylphosphatidylinositol-specific phospholipase C. J Cell Physiol. 1992;151:126-137.
17. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 1988;107: 743-751.
18. Ishai-Michaeli R, Svahn C-M, Chajek-Shaul T, Korner G, Ekre H-P, Vlodavsky I. Importance of size and sulfation of heparin in release of basic fibroblast factor from the vascular endothelium and extracellular matrix. Biochemistry. 1992;31:2080-2088.
19. Ishai-Michaeli R, Eldor A, Vlodavsky I. Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul. 1990;1:833-842.
20. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64: 841-848.
21. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol. 1992;12:240-247.
22. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994; 79:1015-1024.
23. Regan J, Ben-Sasson SA, Sabatino R, Eilat D, Bruno JG, D'Alisa R, Chang MN. Mimicry of biological macromolecules by polyaromatic anionic compounds. J Bioact Compat Polymer. 1993;8: 317-337.
24. Benezra M, Vlodavsky I, Yayon A, Bar-Shavit R, Regan J, Chang M, Ben-Sasson SA. Reversal of basic fibroblast growth factor-mediated autocrine cell transformation by aromatic anionic compounds. Cancer Res. 1992;52:5656-5662.
25. Benezra M, Ben-Sasson SA, Regan J, Chang M, Bar-Shavit R, Vlodavsky I. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds. Arterioscler Thromb. 1994;14:1992-1999.
26. Whalen GF, Shing Y, Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors. 1989;1: 157-164.
27. Thompson RW, Whalen GF, Saunders KB, Hores T, D'amore PA. Heparin-mediated release of fibroblast growth factor-like activity into the circulation of rabbits. Growth Factors. 1990;3:221-229.
28. Castellot JJ, Choay J, Lormeau J-C, Petitou M, Sache E, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells, II: evidence for a penta saccharide sequence that contains a 3-O-sulfate group. J Cell Biol. 1986;102:1979-1984.
29. Schmidt A, Yoshida K, Buddecke E. The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues. J Biol Chem. 1992;267:19242-19247.
30. Tsukada T, McNutt MA, Ross R, Gown AM. HHF35, a muscle actin-specific monoclonal antibody, II: reactivity in normal, reactive, and neoplastic human tissues. Am J Pathol. 1987;127: 389-402.
31. Gospodarowicz D, Moran J, Braun D, Birdwell C. Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. Proc Natl Acad Sci U S A. 1976;73:4120-4124.
32. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michali R, Sasse J, Klagsbrun M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A. 1987;84:2292-2296.
33. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol. 1987;13:123-130.
34. Nguyen HC, Grossi EA, LeBoutillier M, Steinberg BM, Rifkin DB, Baumann FG, Colvin SB, Galloway AC. Mammary artery versus saphenous vein grafts: assessment of basic fibroblast growth factor receptors. Ann Thorac Surg. 1994;58:308-310.
35. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992;90:2013-2021.
36. Edelman ER, Karnovsky MJ. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation. 1994;89:770-776.
37. Moscatelli D. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors: implications for mechanisms of bFGF release from pericellular matrix. J Biol Chem. 1992;267:25803-25809.
38. Wright TC, Castellot JJ, Karnovsky MJ. Regulation of cellular proliferation by heparin and heparan sulfate. In: Lane DA, Lindahl U, eds. Heparin. London, England: Edward Arnold; 1989:295-316.
39. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev. 1991;71:481-539.
40. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265: 625-626.
41. Ellis SG, Roubin GS, Wilentz J, Douglas J, King S. Effect of 18- to 24-hour heparin administration for prevention of restenosis. Am Heart J. 1989;117:777-782.
42. Lehmann KG, Doria RJ, Feuer JM, Hall PX, Hoang DT. Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial. J Am Coll Cardiol. 1991;17:181A. Abstract.
43. Rapraeger A, Krufka A, Olwin BR. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science. 1991;252:1705-1708.
44. Vlodavsky I, Miao H, Atzmon R, Levi E, Zimmermann J, Bar-Shavit R, Peretz T, Ben-Sasson SA. Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Thromb Haemost. 1995;74:534-540.
45. Riess FC, Lower C, Seelig C, Bleese N, Kormann J, Muller BG, Potzsch B. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg. 1995;110:265-267.
46. Meyer BJ, Fernandez OA, Mailhac A, Falk E, Badimon L, Michael AD. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation. 1994;90:2474-2480.
47. Walters TK, Gorog DA, Wood RF. Thrombin generation following arterial injury is a critical initiating event. J Vasc Res 1994;31: 173-177.
48. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R, Ekre H, Svahn CM. Modulation of neovascularization and metastasis by species of heparin. Adv Exp Biol. 1992;313:317-327.
49. Pukac L, Castellot JJ Jr, Wright T, Caleb B, Karnovsky MJ. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul. 1990;1:435-443.
50. Yamaguchi M, Diamond S, Watanabe H, Gallati H, Baur W, Sharefkin JB. Heparin and dibutyryl cAMP modulate gene expression in stimulated human saphenous vein smooth muscle cells. In Vitro Cell Dev Biol Anim. 1993;29A:867-872.
51. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995;16:198-204.
52. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation. 1988;77:1022-1029.
53. Thompson RW, Orlidge A, D'amore PA. Heparin and growth control of vascular cells. Ann N Y Acad Sci. 1989;556:255-267.